Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders Sells 2,635 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,635 shares of Revolution Medicines stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now owns 96,470 shares of the company’s stock, valued at $4,379,738. This trade represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jack Anders also recently made the following trade(s):

• On Friday, October 11th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The stock was sold at an average price of $50.30, for a total transaction of $503,000.00.

Revolution Medicines Trading Down 4.8 %

RVMD traded down $2.16 during midday trading on Wednesday, hitting $43.00. 1,019,225 shares of the company traded hands, compared to its average volume of 1,392,216. The business has a 50 day simple moving average of $52.23 and a two-hundred day simple moving average of $46.05. Revolution Medicines, Inc. has a 52-week low of $25.60 and a 52-week high of $62.40. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of -11.98 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). During the same quarter in the previous year, the firm earned ($0.99) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on RVMD shares. HC Wainwright upped their target price on Revolution Medicines from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Piper Sandler increased their price objective on Revolution Medicines from $57.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a report on Tuesday, December 3rd. Barclays increased their price target on shares of Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, September 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $68.00 target price on shares of Revolution Medicines in a report on Tuesday, December 3rd. Eleven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Revolution Medicines presently has an average rating of “Buy” and an average target price of $63.67.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC lifted its stake in Revolution Medicines by 30.0% in the 2nd quarter. Farallon Capital Management LLC now owns 9,757,692 shares of the company’s stock worth $378,696,000 after purchasing an additional 2,249,820 shares in the last quarter. Janus Henderson Group PLC lifted its position in Revolution Medicines by 32.3% during the third quarter. Janus Henderson Group PLC now owns 6,137,244 shares of the company’s stock worth $278,280,000 after buying an additional 1,497,026 shares in the last quarter. FMR LLC boosted its stake in Revolution Medicines by 4.4% during the third quarter. FMR LLC now owns 5,875,893 shares of the company’s stock worth $266,472,000 after buying an additional 250,037 shares during the last quarter. State Street Corp grew its holdings in Revolution Medicines by 4.1% in the 3rd quarter. State Street Corp now owns 5,279,584 shares of the company’s stock valued at $239,429,000 after buying an additional 208,516 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Revolution Medicines by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,627,025 shares of the company’s stock worth $164,517,000 after acquiring an additional 291,369 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.